Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature

Int J Antimicrob Agents. 2013 Nov;42(5):450-5. doi: 10.1016/j.ijantimicag.2013.07.005. Epub 2013 Aug 11.

Abstract

Data regarding ceftaroline use for meticillin-resistant Staphylococcus aureus bacteraemia (MRSAB) are lacking. Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. Clinical success was observed in 23 patients (74.2%). Adverse events associated with prolonged therapy were rare and included eosinophilic pneumonia, rash and diarrhoea. We conclude that ceftaroline can be used for MRSAB.

Keywords: Bacteraemia; Ceftaroline; Endocarditis; MRSA; Meticillin-resistant Staphylococcus aureus.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Cephalosporins / therapeutic use*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Female
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification*
  • Middle Aged
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • T 91825